Type 2 Diabetes - Drug Pipeline Analysis and Market Forecasts to 2016

Type-2 Diabetes - Drug Pipeline Analysis and Market Forecasts to 2016

Summary

GlobalData, the industry analysis specialist’s new report on the pharmaceutical and healthcare sector, “Type 2 Diabetes – Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global type 2 diabetes market. The report identifies the key trends shaping and driving the global type 2 diabetes market, a key segment within the pharma industry. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global type 2 diabetes sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Scope

The scope of the report includes:

• Annualized global type-2 diabetes therapeutics market revenues data from 2001 to 2009, forecast forward for 7 years to 2016.
• Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
• Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. Key classes of mechanisms of action include SGLT-2 inhibitors, 11β HSD inhibitors, CCR2 antagonists, selective inhibitors of fructose 1,6-bisphosphatase, immune modulators, cortisol synthesis Inhibitors, interleukin-1β antagonists, gastrin-releasing peptide (GRP) receptor agonists, GPR 119 agonists,TLR-4 receptor agonists, FXR antagonists and antisense drugs targeting glucagon receptor.
• Analysis of the current and future market competition in the global type-2 diabetes therapeutics market. Key future market players covered are Hoffmann-La Roche, Novo Nordisk, Merck & Co., Novartis Ag, Sanofi-aventis, Eli Lilly & Company and GlaxoSmithKline.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with type-2 diabetes market.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

• Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global type 2 diabetes market.
• Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global type 2 diabetes market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global type 2 diabetes market landscape? – Identify, understand and capitalize.

1 Table of contents

1.1 List of Tables

1.2 List of Figures

2 Type-2 Diabetes Therapeutics Market: Market Characterization

2.1 Overview

2.2 Type-2 Diabetes Market Size

2.3 Type-2 Diabetes Market Forecast and CAGR

2.4 Drivers and Barriers for Type-2 Diabetes Market

2.4.1 Drivers for Type-2 Diabetes Market

2.4.2 Restraints for Type-2 Diabetes Market

2.5 Opportunity and Unmet Need

2.5.1 Unmet Needs

2.5.2 Impact Analysis of Unmet Needs

2.6 Key Takeaway

3 Type-2 Diabetes Therapeutics Market: Competitive Assessment

3.1 Overview

3.2 Strategic Competitor Assessment

3.3 Product Profile for the Major Marketed Products in the Type-2 Diabetes Market

3.3.1 Actos (pioglitazone)

3.3.2 Avandia (rosiglitazone)

3.3.3 Januvia (sitagliptin)

3.3.4 Starlix (nateglinide)

3.3.5 Byetta (exenatide)

3.3.6 Lantus (insulin glargine)

3.3.7 Levemir (insulin detemir)

3.4 Key Takeaway

4 Type-2 Diabetes Therapeutics Market: Pipeline Assessment

4.1 Overview

4.2 Strategic Pipeline Assessment

4.2.1 Technology Trends Analytic Framework

4.3 Type-2 Diabetes Therapeutics - Promising Drugs under Clinical Development

4.4 Molecule Profile for Promising Drugs under Clinical Development

4.4.1 BMS-512148 (dapagliflozin)

4.4.2 Victoza

4.4.3 D-Tagatose

4.4.4 JNJ-28431754 (canagliflozin)

4.4.5 MB07803

4.5 Type-2 Diabetes Therapeutics Market - Clinical Pipeline by Mechanism of Action

4.6 Type-2 Diabetes Pipeline - Pipeline by Clinical Phases of Development

4.6.1 Type-2 Diabetes Therapeutics - Regulatory Filing and Phase III Clinical Pipeline

4.6.2 Type-2 Diabetes Therapeutics - Phase II Clinical Pipeline

4.6.3 Type-2 Diabetes Therapeutics - Phase I Clinical Pipeline

4.6.4 Type-2 Diabetes Therapeutics - Preclinical Pipeline

4.6.5 Type-2 Diabetes Therapeutics - Discovery Pipeline

4.7 Discontinued / Suspended Drugs for Type-2 Diabetes

4.8 Key Takeaway

5 Type-2 Diabetes Therapeutics Market: Implications for Future Market Competition

6 Type-2 Diabetes Therapeutics Market: Future Players in Type-2 Diabetes Market

6.1 Introduction

6.2 GlaxoSmithKline

6.2.1 Company Overview

6.2.2 Business Description

6.2.3 Type-2 Diabetes Therapeutics Portfolio

6.3 Hoffmann-La Roche

6.3.1 Company Overview

6.3.2 Business Description

6.3.3 Type-2 Diabetes Therapeutics Portfolio

6.4 Novo Nordisk

6.4.1 Overview

6.4.2 Type-2 Diabetes Therapeutics Portfolio

6.5 Merck & Co.

6.5.1 Overview

6.5.2 Business Description

6.5.3 Type-2 Diabetes Therapeutics Portfolio

6.6 Novartis Ag

6.6.1 Company Overview

6.6.2 Business Description

6.6.3 Type-2 Diabetes Therapeutics Portfolio

6.7 Sanofi-aventis

6.7.1 Company Overview

6.7.2 Business Description

6.7.3 Type-2 Diabetes Therapeutics Portfolio

6.8 Eli Lilly & Company

6.8.1 Overview

6.8.2 Type-2 Diabetes Therapeutics Portfolio

7 Type-2 Diabetes Therapeutics Market: Appendix

7.1 Definitions

7.2 Acronyms

7.3 Research Methodology

7.3.1 Coverage

7.3.2 Secondary Research

7.3.3 Forecasting

7.3.4 Primary Research

7.3.5 Expert Panel validation

7.4 Contact Us

7.5 Disclaimer

7.6 Sources